Quantitation of plasmatic lysosphingomyelin and lysosphingomyelin-509 for differential screening of Niemann-Pick A/B and C diseases

L. Kuchar, J. Sikora, Maria E. Gulinello, H. Poupetova, A. Lugowska, V. Malinova, H. Jahnova, B. Asfaw, J. Ledvinova

Research output: Contribution to journalArticle

21 Scopus citations


Acid sphingomyelinase deficiency (ASMd, Niemann-Pick disease A/B) and Niemann-Pick type C disease (NPC) share core clinical symptoms. Initial diagnostic discrimination of these two rare lysosomal storage diseases is thus difficult. As sphingomyelin accumulates in ASMd as well as NPC, lysosphingomyelin (sphingosylphosphorylcholine) and its m/z 509 analog were suggested as biomarkers for both diseases. Herein we present results of simultaneous LC-ESI-MS/MS measurements of lysosphingomyelin and lysosphingomyelin 509 in plasma and dried blood spots (DBS) collected from ASMd and NPC patients and suggest that the plasma but not DBS levels of the two analytes allow differential biochemical screening of ASMd and NPC.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalAnalytical Biochemistry
StatePublished - May 15 2017



  • Lysosphingomyelin
  • Mass spectrometry
  • Niemann-Pick A/B
  • Niemann-Pick C
  • Screening
  • Sphingosylphosphorylcholine

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this